329. exacerbation of chronic hepatitis B. J Hepatol 2003;38:322-327.
330. Moon W, Choi MS, Moon YM, Paik SW, Lee JH, Koh KC, et al. Efficacy and safety of adefovir dipivoxil in patients with decompensated liver cirrhosis with Lamivudine resistance compared to patients with compensated liver disease. Korean J Hepatol 2005;11:125-134.
331. Schalm SW, Heathcote J, Cianciara J, Farrell G, Sherman M, Willems B, et al. Lamivudine and alpha interferon combination treatment of patients with chronic hepatitis B infection: a randomised trial. Gut 2000;46:562-568.
332. Schiff ER, Dienstag JL, Karayalcin S, Grimm IS, Perrillo RP, Husa P, et al. Lamivudine and 24 weeks of lamivudine/interferon combination therapy for hepatitis B e antigen-positive chronic hepatitis B in interferon nonresponders. J Hepatol 2003;38:818-826.
333. Wursthorn K, Lutgehetmann M, Dandri M, Buggisch P, Zollner B, Longerich T, et al. Peginterferon alpha-2b plus adefovir induce strong cccDNA decline and HBsAg reduction in patients with chronic hepatitis B. Hepatology 2006;44:675-684.
334. Sung JJ, Lai JY, Zeuzem S, Chow WC, Heathcote EJ, Perrillo RP, et al. Lamivudine compared with lamivudine and adefovir dipivoxil for the treatment of HBeAg-positive chronic hepatitis B. J Hepatol 2008;48:728-735.
335. Hui CK, Zhang HY, Bowden S, Locarnini S, Luk JM, Leung KW, et al. 96 weeks combination of adefovir dipivoxil plus emtricitabine vs. adefovir dipivoxil monotherapy in the treatment of chronic hepatitis B. J Hepatol 2008;48:714-720.
336. Carey I, Harrison PM. Monotherapy versus combination therapy for the treatment of chronic hepatitis B. Expert Opin Investig Drugs 2009;18:1655-1666.
337. Chevalier S, Bouvier Alias M, Laperche S, Pawlotsky J. Performance of the Cobas AmpliPrep/Cobas TaqMan real-time PCR assay for hepatitis B virus DNA quantification. J Clin Microbiol 2008;46:1716-1723.
338. Afdhal NH, Lok AS, Di Bisceglie AM. Clinical decisions. Management of incidental hepatitis C virus infection. N Engl J Med 2009;360:1902-1906.
339. Ahn SH, Chan HL, Chen PJ, Cheng J, Goenka MK, Hou J, et al. Chronic hepatitis B: whom to treat and for how long? Propositions, challenges, and future directions. Hepatol Int 2010;4:386-395.
340. Ahn SH, Yuen L, Revill P. Clarification required for the definition of hepatitis B virus subgenotypes C1 and C2. Intervirology 2009;52:321-322.
341. Lee JM, Ahn SH. Quantification of HBsAg: basic virology for clinical practice. World J Gastroenterol 2011;17:283-289.
342. Lee JM, Ahn SH, Kim HS, Park H, Chang HY, Kim do Y, et al. Quantitative hepatitis B surface antigen and hepatitis B e antigen titers in prediction of treatment response to entecavir. Hepatology 2011;53:1486-1493.
343. Kim do Y, Ahn SH, Lee HW, Park JY, Kim SU, Paik YH, et al. Clinical course of virologic breakthrough after emergence of YMDD mutations in HBeAg-positive chronic hepatitis B. Intervirology 2008;51:293-298.
344. Lee JM, Park JY, Kim do Y, Nguyen T, Hong SP, Kim SO, et al. Long-term adefovir dipivoxil monotherapy for up to 5 years in lamivudine-resistant chronic hepatitis B. Antivir Ther 2010;15:235-241.
345. Lee JM, Kim HJ, Park JY, Lee CK, Kim do Y, Kim JK, et al. Rescue monotherapy in lamivudine-resistant hepatitis B e antigen-positive chronic hepatitis B: adefovir versus entecavir. Antivir Ther 2009;14:705-712.
346. Kim H, Han K, Ahn SH, Kim EO, Chang HY, Moon MS, et al. Evaluation of methods for monitoring drug resistance in chronic hepatitis B patients during lamivudine therapy based on mass spectrometry and reverse hybridization. Antivir Ther 2005;10:441-449.
347. Han KH, Hong SP, Choi SH, Shin SK, Cho SW, Ahn SH, et al. Comparison of multiplex restriction fragment mass polymorphism and sequencing analyses for detecting entecavir resistance in chronic hepatitis B. Antivir Ther 2011;16:77-87.
348. Liaw YF, Xie Q, Han KH, Gane EJ, Piratvisuth T, McCloud PI, et al. Shorter duration and lower dose of

<PAGE>114